Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 pegcetacoplan vs sham for geographic atrophy secondary to age-related macular degeneration
NL-OMON55547Phase 3Active, not recruiting
- Sponsor
- Apellis Pharmaceuticals
- Start
- Dec 2019
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pegcetacoplan in age-related macular degeneration (AMD) (2 arms), sponsored by Apellis Pharmaceuticals. Primary endpoint: Change from baseline to Month 12 in total area of geographic atrophy lesions. Started Dec 2019; status: active, not recruiting.
02
Drugs
pegcetacoplan
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NL-OMON55547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55547.